Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15730210 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1KMT2ASLC18A3SIGMAR1 | |
| SCHEMBL20983529 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1KMT2ASLC18A3SIGMAR1 | |
| SCHEMBL15730213 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1KMT2ASLC18A3SIGMAR1 | |
| SCHEMBL19776738 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1KMT2ASLC18A3SIGMAR1 | |
| SCHEMBL25322420 | 0.88 | TSHR (0.46) | SMN1; SMN2MEN1KMT2ASLC18A3SIGMAR1 | |
| SCHEMBL25322414 | 0.88 | TSHR (0.46) | SMN1; SMN2MEN1KMT2ASLC18A3SIGMAR1 | |
| SCHEMBL24367529 | 0.88 | TSHR (0.46) | SMN1; SMN2MEN1KMT2ASLC18A3SIGMAR1 | |
| SCHEMBL29081860 | 0.88 | TSHR (0.46) | SMN1; SMN2MEN1KMT2ASLC18A3SIGMAR1 | |
| SCHEMBL24366653 | 0.88 | TSHR (0.46) | SMN1; SMN2MEN1KMT2ASLC18A3SIGMAR1 | |
| Fumaric Acid SCHEMBL9080832 | 0.86 | KCNH2 (0.40) | SMN1; SMN2KCNH2SCN3ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230121302-A1 | METHODS OF IRON CATALYZED C-H BOND AMINATION | VERSITECH LIMITED (CN) | 2023-04-20 | — | — | US | disclosed |
| US-10995056-B2 | Direct C—H amination and aza-annulation | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-05-04 | — | — | US | disclosed |
| EP-3233858-B1 | ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190152892-A1 | DIRECT C-H AMINATION AND AZA-ANNULATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-05-23 | — | — | US | disclosed |
| WO-2018013540-A1 | DIRECT C-H AMINATION AND AZA-ANNULATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-01-18 | — | — | WO | disclosed |
| US-20170266167-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | UNIVERSITY OF WASHINGTON (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | UNIVERSITY OF WASHINGTON (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244197-A1 | Antibacterial agents | MRPL21, SI, PGLS | SMN1; SMN2 2296/4885MEN1 2414/4885KMT2A 4800/4885 |
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | SMN1; SMN2 2296/4885MEN1 2414/4885KMT2A 4800/4885 |
| US-20170266167-A1 | ERK INHIBITORS | MAPK1, MAPK3, MAPK6 | SMN1; SMN2 3550/4885MEN1 2109/4885KMT2A 3239/4885 |
| US-10995056-B2 | Direct C—H amination and aza-annulation | AOC3, ALKBH3, AZI2 | SMN1; SMN2 3039/4885MEN1 2508/4885KMT2A 550/4885 |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | SMN1; SMN2 2296/4885MEN1 2414/4885KMT2A 4800/4885 |
| US-20230121302-A1 | METHODS OF IRON CATALYZED C-H BOND AMINATION | FTH1, FECH, HCCS | SMN1; SMN2 3634/4885MEN1 2070/4885KMT2A 624/4885 |
| US-20190152892-A1 | DIRECT C-H AMINATION AND AZA-ANNULATION | AOC3, ALKBH3, AZI2 | SMN1; SMN2 2895/4885MEN1 2673/4885KMT2A 591/4885 |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | SMN1; SMN2 2296/4885MEN1 2414/4885KMT2A 4800/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | SMN1; SMN2 3500/4885MEN1 2645/4885KMT2A 2804/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | SMN1; SMN2 3500/4885MEN1 2645/4885KMT2A 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.